Overview
Neurogenix Therapeutics develops small-molecule neurotrophin mimetics targeting TrkB receptors to treat treatment-resistant depression and cognitive decline.
More in Neuropharmaceuticals
Latest industry news
Flourish Emerges from Stealth with Bezos and Google Ventures Backing to Advance Neuroscience Therapeutics
2026-07-24 ยท Funding
Science Corp. Launches Prima BCI Implant in Europe, Bringing Vision Restoration to a New Market
2026-07-23 ยท Product
First Able-Bodied Individuals Receive Brain-Computer Implants in Landmark Expansion of BCI Eligibility
2026-07-22 ยท Research
Closed-Loop BCIs Charted as Next Frontier for Depression, Anxiety, and PTSD Treatment
2026-07-21 ยท Research
Company details
Category
๐ Neuropharmaceuticals
Location
Basel, Switzerland
Funding
$28M Series B
Website
neurogenixtherapeutics.comListed
2026-06-29
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages โ